Meridian Investment Counsel Inc. lifted its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 62,359 shares of the biopharmaceutical company’s stock after purchasing an additional 213 shares during the period. Pfizer comprises about 1.3% of Meridian Investment Counsel Inc.’s holdings, making the stock its 19th largest position. Meridian Investment Counsel Inc.’s holdings in Pfizer were worth $2,133,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares in the last quarter. Orrstown Financial Services Inc. increased its position in shares of Pfizer by 23.0% during the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 612 shares in the last quarter. Cable Hill Partners LLC increased its position in shares of Pfizer by 6.0% during the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 265 shares in the last quarter. Acropolis Investment Management LLC increased its position in shares of Pfizer by 1.9% during the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 100 shares in the last quarter. Finally, Cohen Lawrence B acquired a new stake in shares of Pfizer during the first quarter worth about $201,000. Institutional investors and hedge funds own 69.09% of the company’s stock.
A number of research firms recently issued reports on PFE. BMO Capital Markets reissued a “buy” rating and set a $37.00 price target on shares of Pfizer in a report on Thursday. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target on the stock. in a report on Wednesday. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Thursday, August 24th. Berenberg Bank reissued a “hold” rating and set a $36.00 price target (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Finally, Cowen and Company set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $37.72.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by insiders.
Shares of Pfizer, Inc. (NYSE PFE) traded down 1.04% on Friday, reaching $35.36. The company’s stock had a trading volume of 28,871,059 shares. The stock has a 50-day moving average of $33.64 and a 200 day moving average of $33.53. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.84. The stock has a market capitalization of $210.30 billion, a PE ratio of 25.87 and a beta of 1.00.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share. On average, equities analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were given a $0.32 dividend. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.62%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with our FREE daily email newsletter.